REDWOOD CITY, Calif.,
May 1, 2015 AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute and breakthrough
pain, today announced that Timothy E.
Morris, chief financial officer will be participating
in three upcoming investor events. Details of the events are
as follows:
Mizuho Third Annual Healthcare Corporate Access
Day
Date: Tuesday, May 5
Location: The Omni Berkshire Place, New York
Bank of America Healthcare Conference 2015
Date:
Tuesday, May 12
Location: Encore at the Wynn, Las
Vegas
Presentation Time: 12 pm PT, 3 pm
ET
UBS Global Healthcare Conference
Date:
Monday, May 18
Location: Sheraton Times Square Hotel, New York
The Bank of America conference presentation will be webcast live
and can be accessed through the Investors page at
www.acelrx.com. For those not available to listen to the live
broadcast, a replay will be archived for 90 days and available
through the Investors page on www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company
focused on the development and commercialization of innovative
therapies for the treatment of acute and breakthrough pain.
AcelRx's lead product candidate, Zalviso, is designed for the
management of moderate-to-severe acute pain in adult patients in
the hospital setting by utilizing a high therapeutic index opioid,
through a non-invasive delivery route via a pre-programmed,
patient-controlled analgesia device. AcelRx has announced positive
results from each of the three completed Phase 3 clinical trials
for Zalviso, and has submitted an NDA to the FDA seeking approval
for Zalviso in the treatment of moderate-to-severe acute pain in
adult patients in the hospital setting and on July 25, 2014, received a Complete Response
Letter from the FDA. AcelRx received correspondence from the FDA
stating that in addition to the bench testing and two Human Factors
studies AcelRx has performed, an additional clinical study is
needed to assess the risk of inadvertent dispensing and overall
risk of dispensing failures. AcelRx plans to meet with the FDA to
discuss and understand the need and potential objectives of an
additional clinical study for Zalviso. AcelRx has initiated a Phase
3 clinical trial for ARX-04, a product candidate for the treatment
of moderate-to-severe acute pain in a medically supervised
setting.
For additional information about AcelRx's clinical programs,
please visit www.acelrx.com.
Logo -
http://photos.prnewswire.com/prnh/20130226/MM67303LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-participate-at-upcoming-investor-conferences-in-may-300075433.html
SOURCE AcelRx Pharmaceuticals, Inc.